NCT03768570

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2019-10-25Est. Completion: 2026-10-31

Enrollment target: 82 participants

Locations

Tom Baker Cancer Centre, Calgary, Alberta, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Health Sciences North, Greater Sudbury, Ontario, Canada
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Kingston Health Sciences Centre, Kingston, Ontario, Canada
London Regional Cancer Program, London, Ontario, Canada
Stronach Regional Health Centre at Southlake, Newmarket, Ontario, Canada
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Thunder Bay Regional Health Sciences Centre/, Thunder Bay, Ontario, Canada
University Health Network, Toronto, Ontario, Canada
The Jewish General Hospital, Montreal, Quebec, Canada
The Research Institute of the McGill University, Montreal, Quebec, Canada
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
Hospital Clinic i Provincial, Barcelona, Spain

Other microbiome trials you might be interested in

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsPhase 1Recruiting

Breast CancerSmall Cell Lung CancerOvarian CancerGastric CancerHormone-receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerAdvanced Solid TumorEndometrial CancerProstate CancerTNBC - Triple-Negative Breast CancerGastroEsophageal CancerBladder Cancer

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to a…

Newport Beach, United StatesEst. completion Aug 31, 2026

View Trial →

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.